Cargando…

Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study)

AIMS/INTRODUCTION: To compare the treatment satisfaction of four classes of oral hypoglycemic agents (OHAs): dipeptidyl peptidase‐4 (DPP‐4) inhibitors, α‐glucosidase inhibitors (αGI), biguanides (BG) and sulfonylureas (SU), which are common initial treatments for type 2 diabetes mellitus patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Hitoshi, Hayashino, Yasuaki, Akai, Yasuhiro, Yabuta, Matahiro, Tsujii, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754532/
https://www.ncbi.nlm.nih.gov/pubmed/28296349
http://dx.doi.org/10.1111/jdi.12659
_version_ 1783290436137254912
author Ishii, Hitoshi
Hayashino, Yasuaki
Akai, Yasuhiro
Yabuta, Matahiro
Tsujii, Satoru
author_facet Ishii, Hitoshi
Hayashino, Yasuaki
Akai, Yasuhiro
Yabuta, Matahiro
Tsujii, Satoru
author_sort Ishii, Hitoshi
collection PubMed
description AIMS/INTRODUCTION: To compare the treatment satisfaction of four classes of oral hypoglycemic agents (OHAs): dipeptidyl peptidase‐4 (DPP‐4) inhibitors, α‐glucosidase inhibitors (αGI), biguanides (BG) and sulfonylureas (SU), which are common initial treatments for type 2 diabetes mellitus patients in Japan, and to identify the best oral hypoglycemic agent in terms of treatment satisfaction. MATERIALS AND METHODS: In this 12‐week, randomized, controlled, open‐label study, Japanese outpatients with type 2 diabetes mellitus who were naïve to pharmacological treatment were randomly assigned a DPP‐4 inhibitor, a BG., an αGI or a SU. The primary end‐point was the Oral Hypoglycemic Agent Questionnaire (OHA‐Q) total and subscale scores (treatment convenience, somatic symptoms and satisfaction) at week 4. Adherence, glycated hemoglobin (HbA1c) level and safety were also evaluated. RESULTS: The DPP‐4 inhibitor group scored highest in the OHA‐Q total and all subscale scores at week 4. The total score was significantly higher in the DPP‐4 inhibitor group than in the BG or αGI groups (P = 0.0084 and 0.0147, respectively). The mean total score at week 12 was also highest in the DPP‐4 inhibitor group, with a significant difference compared with the αGI group (P = 0.0293). The mean HbA1c decreased from baseline to week 12 in all groups. The DPP‐4 inhibitor group had the highest adherence at weeks 4 and 12. A total of 11 patients reported adverse events, including one hypoglycemic event in the SU group. CONCLUSIONS: The DPP‐4 inhibitor was the most preferable option in terms of treatment satisfaction.
format Online
Article
Text
id pubmed-5754532
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57545322018-01-09 Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study) Ishii, Hitoshi Hayashino, Yasuaki Akai, Yasuhiro Yabuta, Matahiro Tsujii, Satoru J Diabetes Investig Articles AIMS/INTRODUCTION: To compare the treatment satisfaction of four classes of oral hypoglycemic agents (OHAs): dipeptidyl peptidase‐4 (DPP‐4) inhibitors, α‐glucosidase inhibitors (αGI), biguanides (BG) and sulfonylureas (SU), which are common initial treatments for type 2 diabetes mellitus patients in Japan, and to identify the best oral hypoglycemic agent in terms of treatment satisfaction. MATERIALS AND METHODS: In this 12‐week, randomized, controlled, open‐label study, Japanese outpatients with type 2 diabetes mellitus who were naïve to pharmacological treatment were randomly assigned a DPP‐4 inhibitor, a BG., an αGI or a SU. The primary end‐point was the Oral Hypoglycemic Agent Questionnaire (OHA‐Q) total and subscale scores (treatment convenience, somatic symptoms and satisfaction) at week 4. Adherence, glycated hemoglobin (HbA1c) level and safety were also evaluated. RESULTS: The DPP‐4 inhibitor group scored highest in the OHA‐Q total and all subscale scores at week 4. The total score was significantly higher in the DPP‐4 inhibitor group than in the BG or αGI groups (P = 0.0084 and 0.0147, respectively). The mean total score at week 12 was also highest in the DPP‐4 inhibitor group, with a significant difference compared with the αGI group (P = 0.0293). The mean HbA1c decreased from baseline to week 12 in all groups. The DPP‐4 inhibitor group had the highest adherence at weeks 4 and 12. A total of 11 patients reported adverse events, including one hypoglycemic event in the SU group. CONCLUSIONS: The DPP‐4 inhibitor was the most preferable option in terms of treatment satisfaction. John Wiley and Sons Inc. 2017-05-02 2018-01 /pmc/articles/PMC5754532/ /pubmed/28296349 http://dx.doi.org/10.1111/jdi.12659 Text en © 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Ishii, Hitoshi
Hayashino, Yasuaki
Akai, Yasuhiro
Yabuta, Matahiro
Tsujii, Satoru
Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study)
title Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study)
title_full Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study)
title_fullStr Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study)
title_full_unstemmed Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study)
title_short Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week, open label, randomized controlled study in Japan (PREFERENCE 4 study)
title_sort dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: results from a multicenter, 12‐week, open label, randomized controlled study in japan (preference 4 study)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754532/
https://www.ncbi.nlm.nih.gov/pubmed/28296349
http://dx.doi.org/10.1111/jdi.12659
work_keys_str_mv AT ishiihitoshi dipeptidylpeptidase4inhibitorsaspreferableoralhypoglycemicagentsintermsoftreatmentsatisfactionresultsfromamulticenter12weekopenlabelrandomizedcontrolledstudyinjapanpreference4study
AT hayashinoyasuaki dipeptidylpeptidase4inhibitorsaspreferableoralhypoglycemicagentsintermsoftreatmentsatisfactionresultsfromamulticenter12weekopenlabelrandomizedcontrolledstudyinjapanpreference4study
AT akaiyasuhiro dipeptidylpeptidase4inhibitorsaspreferableoralhypoglycemicagentsintermsoftreatmentsatisfactionresultsfromamulticenter12weekopenlabelrandomizedcontrolledstudyinjapanpreference4study
AT yabutamatahiro dipeptidylpeptidase4inhibitorsaspreferableoralhypoglycemicagentsintermsoftreatmentsatisfactionresultsfromamulticenter12weekopenlabelrandomizedcontrolledstudyinjapanpreference4study
AT tsujiisatoru dipeptidylpeptidase4inhibitorsaspreferableoralhypoglycemicagentsintermsoftreatmentsatisfactionresultsfromamulticenter12weekopenlabelrandomizedcontrolledstudyinjapanpreference4study